Free Trial

Vaccine Headline Driven Volatility; Wrong-Way Month End Flow

US TSYS SUMMARY
Tsy mostly weaker after the bell, short end outperforming, yield curves broadly steeper as January draws to an end (2s30s +6.1bp; large midmorning block buy +17,733 TUH at 110-15.75). Heavy volumes on late month end flow drew better selling instead of extending duration, approximate volumes in last 5 minutes of trade: TYH1 175k, USH1 35k, 115k FVH1 and 30k TUH.
  • Prior to the sell-off, Tsys pared losses -- headed back to pre-open levels when futures gapped higher on J&J effectiveness headlines. J&J bump didn't last long: follow-up headline notes slightly higher effectiveness in US of 72% and "shot's immunity likely to ramp up over time" Bbg.
  • Second-half support from falling equities (ESH1 -67.0) w/energy sector (refiners, extractors, etc) leading losses. Desks also pointed out risk negative headline: "PFIZER CEO: HIGH POSSIBILITY FUTURE VARIANT WILL ELUDE VACCINES," Bbg added to risk-off tone.
  • Heavy buying in Eurodollar front end, Whites through Reds were +0.010-0.015 for much of day scaled back slightly late. Note 3M LIBOR -0.00312 to 0.20188% (-0.01337/wk) ** 3M New record Low vs. 0.20488% on 11/20/20
  • The 2-Yr yield is down 0.2bps at 0.1152%, 5-Yr is up 1.6bps at 0.443%, 10-Yr is up 4.6bps at 1.091%, and 30-Yr is up 5bps at 1.8545%.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.